Clinical trials
Gastric or Esophagogastric Junction Adenocarcinoma clinical trials
Below are recruiting gastric or esophagogastric junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 930 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06846346RecruitingPhase 2
Testing Ivonescimab with Chemo for Advanced Stomach Cancer
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
LyonAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT06654011RecruitingPhase 2
A study testing a new combination for rare cervical cancer
This trial tests whether adding the drug IN10018 to a standard chemotherapy and immunotherapy combination can help treat a rare type of cervical cancer called gastric-type adenocarcinoma that has spread or come back. The goal is to see if this combination improves outcomes for patients who have already had at least one round of chemotherapy.
Wuhan, HubeiAges 18–75 - NCT04150640RecruitingPhase 2
Chemo drug combination for advanced stomach or esophagus cancer
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Madison, WisconsinAges 18 years+ - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Los Angeles, CaliforniaAges 18 years+ - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT03161522RecruitingPhase 2
Chemo alone versus with radiation or surgery for limited spread
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
Houston, TexasAges 18–79 - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07643623RecruitingPhase 2/Phase 3
Immunotherapy for operable stomach cancer before and after surgery
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07522151RecruitingPhase 3
Adebrelimab with Surgery for Stomach Cancer
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06059495RecruitingPhase 2
Watch-and-wait with dostarlimab for MSI-H stomach cancer
This trial is testing a watch-and-wait approach using the immunotherapy drug dostarlimab for people with a specific type of stomach cancer (dMMR/MSI-H) that hasn't spread. The goal is to see if the drug can eliminate the need for surgery or other treatments.
LilleAges 18–75 - NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT06124963RecruitingPhase 2
WX390 plus Toripalimab for STK11-mutated cervical cancer
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07182565RecruitingPhase 1/Phase 2
Short radiation plus chemotheapy and immunotherapy before surgery for junction cancer
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
Xiamen, FujianAges 18 years+ - NCT07072351RecruitingPhase 1/Phase 2
Radiation plus chemoimmunotherapy for gastroesophageal junction cancer
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
Xiamen, FujianAges 18 years+ - NCT01717924Recruiting
Surgery vs first chemotherapy for stomach signet ring cancer
This trial compares doing surgery first versus starting chemotherapy first for people with resectable signet ring–type stomach cancer. It aims to find which approach works better to cure the cancer and prevent spread.
LilleAges 18–80 - NCT04047953Recruiting
Chemo for stomach cancer to make tumors easier to remove
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Beijing, Beijing MunicipalityAges 18–75 - NCT04821778RecruitingPhase 3
Testing chemoradiotherapy for esophageal and stomach junction cancer
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Anyang, HenanAges 18 years+ - NCT05977998RecruitingPhase 2
Paclitaxel given during surgery for stomach cancer spread to the belly
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
Houston, TexasAges 18 years+ - NCT06385691RecruitingPhase 2
Nutrition app for stomach cancer patients before surgery
This trial tests a smartphone app called myDIET to help people with stomach cancer improve their nutrition before and after surgery. If you are getting chemotherapy or immunotherapy before surgery, you may be able to join.
LyonAges 18 years+ - NCT06415669RecruitingPhase 2
Combination therapy for advanced stomach cancer after immunotherapy
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Fuzhou, FujianAges 18–75 - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+
Hear when a new Gastric or Esophagogastric Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric or esophagogastric junction adenocarcinoma?
- Yes. Clin2 currently lists 930 recruiting gastric or esophagogastric junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric or esophagogastric junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric or esophagogastric junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Adenocarcinoma of Esophagogastric Junction
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Gastric Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.